Wegovy side effects: separating the new reports from the noise

The misconception worth correcting first: 'new' side effects are usually delayed reports, not new discoveries

When people search for new Wegovy side effects, the assumption is often that something unexpected has just surfaced. That is rarely the case. Wegovy carries a Black Triangle (▼) designation from the MHRA, which means healthcare professionals are asked to report any suspected reaction, even familiar ones. The result is an accumulating database that makes less common effects more visible over time, not because they are newly occurring, but because more people are now taking the medicine and reporting their experiences.

The core side-effect profile was established in the STEP clinical trials before UK approval and has remained broadly consistent. What has changed is the quality of post-market data, which has refined understanding of frequency and severity. The broader Wegovy side-effect picture covers the full licensed profile in detail; this page focuses on what has been clarified or formally updated since approval.

One thing the data consistently shows: most reactions are digestive, most are temporary, and most are manageable with sensible titration. If you are curious about what to expect specifically at the 0.5 mg dose, that stage tends to be where people first notice how their body responds to the medicine. Context matters, though, and we will get to the effects that warrant faster action.

What the MHRA has formally updated: pancreatitis and what symptoms to watch for

The most significant regulatory addition to Wegovy's safety profile came on 29 January 2026, when the MHRA issued a Drug Safety Update covering all GLP-1 receptor agonist medicines. Acute pancreatitis (inflammation of the pancreas) was highlighted as an infrequent but potentially serious effect. The MHRA's message was straightforward: if you develop severe, persistent stomach pain that radiates to your back, with or without vomiting, stop taking the medicine and get medical help the same day. You do not need to wait and see whether it settles.

Pancreatitis is listed in Wegovy's prescribing information, so clinicians were already alert to it. The Drug Safety Update reinforced the message at a time when GLP-1 prescribing had expanded significantly. For most people the risk remains low, but low is not zero, and recognising the symptoms early is what makes the difference in outcome.

Gallbladder-related problems (gallstones and gallbladder inflammation) are also noted in post-market data more prominently than early trial reporting suggested. Upper-right abdominal pain or pain after eating fatty food is worth raising with your GP or prescriber promptly. Our guide to the main Wegovy side effects covers the gallbladder picture alongside the GI reactions.

Less-discussed effects that have appeared more clearly in longer-term reporting

Fatigue, dizziness and headaches appear in the formal side-effect lists but tend to receive less attention than nausea. In practice, they catch people off guard, particularly in the first week after a dose increase, which is when they are most likely. Staying well hydrated helps; Wegovy slows gastric emptying, so small sips of fluid throughout the day are more effective than large volumes at once.

Muscle loss has been discussed in the media alongside rapid weight reduction on GLP-1 medicines in general. The current clinical consensus is that this is partly an expected consequence of losing body mass quickly, and that adequate protein intake and resistance exercise can significantly offset it. This is not a newly identified effect (it was observed in the STEP trials) but it has become part of the conversation as more people move through longer treatment courses. The NHS England weight-management injections guidance discusses the importance of lifestyle support alongside the medicine for exactly this reason.

Hair thinning (telogen effluvium) has been raised by patients on Wegovy, as it has with other medicines that produce rapid weight loss. It is believed to reflect the physiological stress of significant calorie reduction rather than a direct drug effect. It generally resolves without treatment. Some people find it reassuring to know in advance; others feel it would have changed their decision. Your prescriber should mention it at consultation so the choice is informed. It is also worth knowing that some people experience no side effects on Wegovy at all, and understanding what that pattern looks like can help you interpret your own experience.

If you are finding side effects more persistent than expected, our page on how long Wegovy side effects last explains what the data suggests about typical timelines.

When to get medical help, and when to contact your prescriber

Same-day emergency care (A&E or 999): severe stomach pain spreading to the back, signs of a serious allergic reaction (swelling of the face, lips or throat; difficulty breathing), rapid heart rate with dizziness or fainting, or sudden changes to your vision if you have diabetes.

Contact your prescriber promptly (that day or the next) for: persistent vomiting or diarrhoea that is preventing you from keeping fluids down, significant upper-right abdominal pain, injection-site reactions that are worsening rather than settling, or any low mood or thoughts of self-harm that feel linked to starting or changing the medicine.

Contact your prescriber at your next check-in for: ongoing nausea beyond three or four weeks at a stable dose, hair changes, fatigue that is not improving, or any side effect that is affecting daily life. Dose timing, injection technique and the pace of titration can all be adjusted, there is usually something practical to try before stopping. You can read more about the practical side of managing reactions to Wegovy on a dedicated page.

If you notice something unexpected that you feel the MHRA should know about (whether or not you think it is related to Wegovy) the Yellow Card scheme at yellowcard.mhra.gov.uk is exactly the right place to report it. You do not need a clinician to submit a report; patients can do it directly.

At nume, our prescribers go through suitability, known risks and what to watch for as part of every consultation. If you have questions before or during treatment, aftercare support is available seven days a week. Start your free consultation to speak with our clinical team.